Kenneth Wong

Kenneth Wong

Auto-generated profile, based on publicly available information

Kenneth Wong

Radiation Oncology Program, Children's Hospital Los Angeles, Los Angeles, CA, United States

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ECEric J. Chow
Eric J. Chow
LALynnette Anderson
Lynnette Anderson
KBK. Scott Baker
K. Scott Baker
SBSmita Bhatia
Smita Bhatia
GGGregory M.T. Guilcher
Gregory M.T. Guilcher
SCSharon M. Castellino
Sharon M. Castellino
Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high-risk hematologic malignancies, solid tumors, and, increasingly, nonmalignant diseases. Given improvements in care, there are a growing number of long-term survivors of pediatric HCT. Compared with childhood cancer survivors who did not undergo transplantation, HCT survivors have a substantially increased burden of serious chronic conditions and impairments involving virtually every organ system and overall quality of life. This likely reflects the joint contributions of pretransplantation treatment exposures and organ dysfunction, the transplantation conditioning regimen, and any post-transplantation graft-versus-host disease (GVHD). In response, the Children's Oncology Group (COG) has created long-term follow-up guidelines (www.survivorshipguidelines.org) for survivors of childhood, adolescent, and young adult cancer, including those who were treated with HCT. Guideline task forces, consisting of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other health care professionals, and patient advocates systematically reviewed the literature with regards to late effects after childhood cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided herein is an organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those who underwent transplantation for nonmalignant diseases, and those with a history of chronic GVHD.

1 May 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DHDaphne Haas-Kogan
Daphne Haas-Kogan
DIDaniel Indelicato
Daniel Indelicato
HPHarald Paganetti
Harald Paganetti
NENatia Esiashvili
Natia Esiashvili
AMAnita Mahajan
Anita Mahajan
LKLarry Kun
Larry Kun

19 September 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Jesse BerryJesse Berry
Jesse Berry
RJRima Jubran
Rima Jubran
JKJonathan W. Kim
Jonathan W. Kim
KWKenneth Wong
Kenneth Wong
SBSimon R. Bababeygy
Simon R. Bababeygy
AMA. Linn Murphree
A. Linn Murphree

1 June 2014 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ECEric J. Chow
Eric J. Chow
KWKenneth Wong
Kenneth Wong
SLStephanie J. Lee
Stephanie J. Lee
KCKara L. Cushing-Haugen
Kara L. Cushing-Haugen
MFMary E.D. Flowers
Mary E.D. Flowers
KBK. Scott Baker
K. Scott Baker
The authors sought to better understand the combined effects of pretransplant, transplant, and post-transplant factors in determining risks of serious cardiovascular disease after hematopoietic cell transplantation (HCT). Hospitalizations and deaths associated with serious cardiovascular outcomes were identified among 1379 Washington State residents who received HCT (57% allogeneic and 43% autologous) at a single center from 1985 to 2005, survived ≥ 2 years, and followed through 2008. Using a nested case-cohort design, relationships (hazard ratios [HRs]) between potential risk factors and outcomes were examined among affected survivors and a randomly selected subcohort (N = 509). After 7.0 years of median follow-up (range, 2.0 to 23.7), the 10-year cumulative incidence of ischemic heart disease, cardiomyopathy, stroke, and all-cause cardiovascular death was 3.8%, 6.0%, 3.5%, and 3.7%, respectively. In multivariable analysis, increased pretransplant anthracycline was associated with cardiomyopathy. Active chronic graft-versus-host disease was associated with cardiovascular death (HR, 4.0; 95% confidence interval, 1.1 to 14.7); risk was otherwise similar between autologous versus allogeneic HCT recipients. Independent of therapeutic exposures, pretransplant smoking, hypertension, dyslipidemia, diabetes, and obesity conferred additional risk of all outcomes except stroke (HR ≥ 1.5 for each additional risk factor, P < .03). Hypertension and dyslipidemia at 1 year with persistence of these conditions 2 or more years after HCT also were associated with independent risks of multiple outcomes. HCT survivors with preexisting or newly developed and persistent cardiovascular risk factors remain at greater risk of subsequent serious cardiovascular disease compared with other survivors, independent of chemo- and radiotherapy exposures. These survivors should receive appropriate follow-up and be considered for primary intervention.

1 April 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CHClayton B. Hess
Clayton B. Hess
HTHolly M. Thompson
Holly M. Thompson
SBStanley H. Benedict
Stanley H. Benedict
JSJ. Anthony Seibert
J. Anthony Seibert
KWKenneth Wong
Kenneth Wong
ACAllen M Chen
Allen M Chen

31 January 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RVRajkumar Venkatramani
Rajkumar Venkatramani
SKSunil Kamath
Sunil Kamath
KWKenneth Wong
Kenneth Wong
AOArthur J Olch
Arthur J Olch
JMJemily Malvar
Jemily Malvar
LMLeo Mascarenhas
Leo Mascarenhas